- Home
- IPST vs ONCO Comparison
IPST vs ONCO Comparison
Compare IPST & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IPST | ONCO |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 3.0M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | IPST | ONCO |
|---|---|---|
| Price | $3.70 | $0.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $164.00 | N/A |
| AVG Volume (30 Days) | ★ 4.7M | 375.3K |
| Earning Date | 04-14-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.80 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,402,488.00 | $815,371.00 |
| Revenue This Year | $70.16 | N/A |
| Revenue Next Year | $60.33 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 5.41 | N/A |
| 52 Week Low | $0.24 | $0.09 |
| 52 Week High | $25.34 | $6.73 |
Technical Indicators
Market Signals| Indicator | IPST | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 45.85 | 50.99 |
| Support Level | $2.75 | $0.61 |
| Resistance Level | $3.95 | $0.99 |
| Average True Range (ATR) | 0.96 | 0.07 |
| MACD | -0.41 | 0.02 |
| Stochastic Oscillator | 1.17 | 42.18 |
Price Performance
Historical ComparisonAbout IPST Heritage Distilling Holding Company Inc.
IP Strategy Holdings Inc operate a diversified business centered on digital asset-based infrastructure and intellectual property (IP) management, supplemented by a legacy craft spirits operating segment. The Company provides public market investors with broad exposure to the around $80 trillion programmable intellectual property economy in a regulated equity format. Its treasury reserve of $IP tokens provides direct participation in the Story ecosystem, which enables on-chain registration, licensing, and monetization of intellectual property.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.